Indefinite- lived intangible impairment
Biogen Indefinite- lived intangible impairment increased by 0.1% to $15.88B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.2%, from $15.91B to $15.88B. Over 5 years (FY 2020 to FY 2025), Indefinite- lived intangible impairment shows an upward trend with a 14.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase in impairment charges signals a decline in the value of the company's intangible assets, potentially indicating poor acquisition outcomes or changing market conditions.
Detailed definition
This represents the gross value of indefinite-lived intangible assets, excluding goodwill, that have been subject to imp...
Peer comparison
Varies significantly based on M&A history; companies with frequent acquisitions often show higher volatility in this metric.
other_intangible_assets_gross_excluding_goodwillHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.64B | $7.61B | $7.61B | $7.61B | $7.60B | $7.59B | $7.48B | $7.49B | $7.51B | $13.14B | $14.23B | $14.23B | $14.27B | $15.95B | $15.95B | $15.91B | $15.89B | $15.89B | $15.87B | $15.88B |
| QoQ Change | — | -0.4% | +0.0% | -0.0% | -0.1% | -0.1% | -1.4% | +0.2% | +0.2% | +75.0% | +8.3% | +0.0% | +0.2% | +11.8% | -0.0% | -0.2% | -0.1% | +0.0% | -0.2% | +0.1% |
| YoY Change | — | — | — | — | -0.5% | -0.2% | -1.7% | -1.5% | -1.2% | +73.1% | +90.3% | +90.0% | +90.0% | +21.4% | +12.0% | +11.8% | +11.4% | -0.4% | -0.5% | -0.2% |
Indefinite- lived intangible impairment at Other Companies
Frequently Asked Questions
- What is Biogen's indefinite- lived intangible impairment?
- Biogen (BIIB) reported indefinite- lived intangible impairment of $15.88B in Q1 2026.
- How has Biogen's indefinite- lived intangible impairment changed year-over-year?
- Biogen's indefinite- lived intangible impairment decreased by 0.2% year-over-year, from $15.91B to $15.88B.
- What is the long-term trend for Biogen's indefinite- lived intangible impairment?
- Over 5 years (2020 to 2025), Biogen's indefinite- lived intangible impairment has grown at a 14.1% compound annual growth rate (CAGR), from $8.22B to $15.87B.
- What does indefinite- lived intangible impairment mean?
- The total value of non-goodwill intangible assets that have been written down due to a loss in value.